Roivant Sciences Names New CEO; Executive Sells Shares
1 report, 1 independent
Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eric Venker assumed the role of CEO at Roivant Sciences on November 1, 2026. Separately, reports noted that Eric Venker, who was previously President and Immunovant CEO of Roivant Sciences Ltd., sold 200,000 common shares on October 28. These sales, which totaled about $7.32 million, were executed under a Rule 10b5-1 trading plan adopted on June 30.
From themarketsdaily.com
Why it matters
The sale of shares by the former executive cut his direct holding by 14.3%. The trades were made under a pre-existing trading plan, which suggests the sale is a weaker signal than a discretionary transaction. Roivant Sciences operates under regulatory requirements enforced by the Securities and Exchange Commission.
From themarketsdaily.com
Who's involved
- Roivant Sciences (United States)The company where the CEO change and share sales occurred
- Securities and Exchange CommissionThe government agency that enforces disclosure requirements for Roivant Sciences
Keep exploring
The entities involved
-
Roivant Sciences (United States)
company in New York, United States